Pharmacoeconomic aspects of bronchial asthma therapy: real clinical practice
https://doi.org/10.21518/2079-701X-2018-15-60-68
Abstract
According to official statistics, over 1.5 million people have BA in the Russian Federation. Direct costs associated with the treatment of BA in the Russian Federation amount to 8.5 billion rubles. The socioeconomic burden of BA put on society, along with temporary and permanent disability, is caused by not only direct, but also indirect costs, as well as costs associated with payments for temporary disability, which leads to a decrease in GDP and GRP (internal gross regional product). The pharmacoeconomic comparison of two alternative drug technologies in the studied groups showed a reasonable opportunity to transfer patients to the drugs that have alternatives produced within the country, confirming that the cost per efficiency unit in using Formisonide-Native and SalticasoneNative is lower than that of drugs produced by a foreign pharmaceutical company (Symbicort Turbuhaler and Seretide Multidisk)
About the Authors
A. S. Belevsky
Pirogov Russian National Research Medical University (RNRMU) of the Ministry of Health of Russia
Russian Federation
Russian Federation
Moscow
A. A. Zaitsev
Burdenko Main Military Clinical Hospital of Russia
Russian Federation
Russian Federation
Moscow
References
1. World Health Organization. Newsletters. Asthma. August 31, 2017. http://www.who.int/ru/news-room/fact-sheets/detail/asthma.
2. Chuchalin AG. Achievements in the treatment of asthma in Russia in the first decade of the new millennium. Consilium Medicum (Extras), 2010: 11-12.
3. Expert Council on Health Care, at the Social Policy Committee of the Federation Council. Socio-economic burden of bronchial asthma and chronic obstructive pulmonary disease in the Russian Federation. M., 2010. 15 p.
4. Decree of the Government of the Russian Federation No. 890 “On state support for the development of the medical industry and improving the provision of population and health care facilities with medicinal products and medical devices” of July 30, 1994
5. Global strategy for the treatment and prevention of bronchial asthma (2011 revision). Translation from English. Under the editorship of Belevsky AS. M.: Russian Respiratory Society, 2012.
6. ГGoryachkina LA, Nenasheva NM. Modern therapy of bronchial asthma. Lechashchiy Vrach, 2002, 04.
7. Lalloo UG, Malolepszy J, Kozma D, Krofta K, Ankerst J, Johansen B, et al. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild_to_moderate asthma. Chest, 2003, 123(5): 1480-7.
8. Kips JC, O’Connor BJ, Inman MD, Svensson K, Pauwels RA, O’Byrne PM. A long_term study of the antiinflammatory effect of low-dose budesonide plus formoterol versus high_dose budesonide in asthma. Am J Respir Crit Care Med, 2000, 161(3 Pt 1): 996-1001.
9. Global Strategy for Asthma Management and Prevention. Global initiative for asthma. 2006 revision. Edited by Chuchalin A. M.: Atmosphere Publishing House, 2007. 104 p.
10. Luss LV, et al. New opportunities in the treatment of bronchial asthma. Pulmonology and otorhinolaryngology. Effektivnaya Farmakoterapiya, 2017, 1: 12-17.
11. Ilyina NI, Shartanova NV, Latysheva EA, Denisov MA. New Russian practitioners’ opportunities in the treatment of uncontrolled asthma. Russian Journal of Allergy, 2014, 5: 51-54.
12. Device assessment, reference: PMINH 1350. 04.07.2017. Pharmaterials ltd. England.
13. State register of maximum selling prices. https://grls.rosminzdrav.ru/pricelims.aspx.
14. Federal clinical guidelines for the diagnosis and treatment of bronchial asthma. Moscow 2016
15. GINA 2018. https://ginasthma.org/2018-ginareport-global-strategy-for-asthma-management-and-prevention/
16. WHO Newsletter N°307 May 2011 http://www.who.int/mediacentre/factsheets/fs307/ru/
17. Appendices 3 to the WHO Global NCD Action Plan 2013–2020. http://who.int/ncds/governance/discussionpaper-updating-appendix3-25july2016-RU.pdf
18. Evaluation of medical technologies and formation of health policies in Europe. European Observatory Series on Health Systems and Policies, Issue 14. Http://www.euro.who.int/__data/assets/pdf_file/0005/128525/e91922R.pdf
19. Ministry of Health of the Russian Federation: Standards of medical care https://www.rosminzdrav.ru/ministry/61/22/stranitsa-979/stranitsa-983
20. Presidential Decree № 598 “On the improvement of the state policy in the field of health care” of May 7, 2012
21. Order of the Ministry of Health of the Russian Federation No. 66 “On approval of the Strategy of drug supply in the Russian Federation for the period till 2025 and plan for its implementation” of February 13, 2013 (as amended on April 07, 2016)
22. Order of the Government of the Russian Federation No. 1662-p “On the concept of the long-term social and economic development of the Russian Federation for the period up to 2020” of November 17, 2008 (as amended on 08.08.2009).
23. Device assessment, reference: PMINH 1350. 14.07.2017. Pharmaterials ltd. England.
Review
For citations:
Belevsky AS, Zaitsev AA. Pharmacoeconomic aspects of bronchial asthma therapy: real clinical practice. Meditsinskiy sovet = Medical Council. 2018;(15):60-68. (In Russ.) https://doi.org/10.21518/2079-701X-2018-15-60-68
Views:
1011
Email this article 